Alcami Appoints Tori E. Arens as President, Drug Product
Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the ...
Biogen outlook disappoints amid pressure on multiple sclerosis franchise
Biogen (NASDAQ:BIIB) shares traded flat in the premarket on Wednesday after the Alzheimer’s drug developer reported better-than-expected Q4 2024 financials while its full-year outlook disappointed due ...
Biogen’s stock hit by soft guidance and a decline in sales of MS drugs
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset ...
Royalty Pharma plc: Royalty Pharma Announces R&D Funding Collaboration With Biogen
Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up ...
Biogen’s (NASDAQ:BIIB) Q4 Sales Top Estimates
Biotech company Biogen (NASDAQ:BIIB) reported revenue ahead of Wall Street’s expectations in Q4 CY2024, with sales up 2.9% ...
A global corporate tax turf war between Trump, the GOP and U.S. allies is brewing
As President Trump threatens a wider trade war on EU and other allies, an obscure global tax battle could be one retaliatory ...
Biogen expects lower 2025 profit as multiple sclerosis drugs face fierce competition
Biogen forecast 2025 profit below last year's levels and Wall Street expectations on Wednesday, hurt by a strong dollar and ...
Biogen 4Q Revenue Tops Wall Street's Estimates
Biogen posted higher-than-expected revenue in its fourth quarter with sales from various products contributing to the top-line. The biotechnology pioneer on Wednesday said it logged net income of $266 ...